Stock Detail
3SBIO INC - AMERICAN DEPOSITARY SHARES EACH REPRESENTING SEVEN ORDINARY SHARES
Sector: Biotechnology
Latest Quote @ Sat May 5 03:49:16 (15 min delayed)
| N/A |
N/A |
$16.59 |
+0.01 |
0.06% |
|
Last Day's Data
| $16.59 |
$16.66 |
$0.01 |
0.06% |
0.00 |
$16.58 |
| $16.58 |
$16.55 |
278,345.00 |
378.65M |
149,962.00 |
22.92 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 16.71 |
16.65 |
16.60 |
16.54 |
16.49 |
Stock Profile
3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People's Republic of China. Its product candidates are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company's principal product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition, the company markets two protein-based therapeutics, Intefen, a recombinant interferon alpha-2a product indicated for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product indicated for the treatment of renal cell carcinoma, metastatic melanoma, thoratic fluid build-up caused by cancer, and tuberculosis. Further, the company's product pipeline includes various protein-based therapeutics, including NuPIAO, a second-generation EPIAO product candidate; TPIAO for the treatment of idiopathic thrombocytopenic purpura; NuLeusin, a next-generation Inleusin product candidate; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through a network of distributors to healthcare providers, including hospitals, clinics, and dialysis centers. It also markets its products through distribution agreements with local agents in various developing countries. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
